Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03679598 · ClinicalTrials.gov registry record · Phase 2
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency
A Phase 2 study of Emphysema or COPD and Alpha-1 Antitrypsin Deficiency (AATD), sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 10
- Study locations
NCT03679598 is a Phase 2 study of Emphysema or COPD and Alpha-1 Antitrypsin Deficiency (AATD) that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 63 participants, roughly in line with the 65-participant average among 7 other Emphysema or COPD trials with a reported enrollment target. The trial reports 10 study locations across 10 states.
The verdict
NCT03679598, a Phase 2 study of Emphysema or COPD and Alpha-1 Antitrypsin Deficiency (AATD), has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase 2, multicenter, double-blind, randomized (1:1), placebo-controlled, 12-week, proof-of-concept study to evaluate the safety and tolerability as well as the mechanistic effect of oral administration of alvelestat (MPH966) in subjects with confirmed AATD defined as Pi\*ZZ, Pi\*SZ, Pi\*null, or another rare phenotype/genotype known to be associated with either low (serum AAT level \<11 μM or \<57.2 mg/dL) or functionally impaired AAT including "F" or "I" mutations.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Alvelestat (MPH966)
Study Locations (10)
Alabama
- The University of Alabama at Birmingham Lung Health Center - Birmingham
California
- UCLA - Los Angeles
Colorado
- National Jewish Health - Denver
New York
- Columbia University - New York
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- Temple University - Philadelphia
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2019-04-08 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03679598
The ClinicalTrials.gov registry entry for NCT03679598 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 65-participant average among 7 other Emphysema or COPD trials with a reported enrollment target. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Emphysema or COPD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03679598 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Alabama, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03679598 about?
NCT03679598 is a clinical study titled "Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency". This is a Phase 2, multicenter, double-blind, randomized (1:1), placebo-controlled, 12-week, proof-of-concept study to evaluate the safety and tolerability as well as the mechanistic effect of oral administration of alvelestat (MPH966) in subjects with confirmed AATD defined as Pi\*ZZ, Pi\*SZ, Pi\*n...
What is the current status of trial NCT03679598?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2019-04-08. Estimated completion is 2023-12-01.
What conditions does trial NCT03679598 study?
This clinical trial studies the following conditions: Emphysema or COPD, Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations.
What interventions are being tested in trial NCT03679598?
The interventions under investigation include: Placebo (OTHER), Alvelestat (MPH966) (DRUG).
Who is sponsoring clinical trial NCT03679598?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03679598 being conducted?
This trial has 10 study locations across Alabama, California, Colorado, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Emphysema or COPD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PiMZ Longitudinal Cohort (PiMZ Logic)
RECRUITING
-
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
RECRUITING · NA
-
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
RECRUITING · NA
-
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
RECRUITING · Phase 1
-
Inter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction
RECRUITING · NA
-
Combined Zephyr Valve System With Inter-lobar Fissure Completion for Lung Volume Reduction in Emphysema
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.